Technology's Checkered Future
Executive SummaryWe review the health care industry’s recent history through the mirror of IN VIVO’s first 100 issues. The biggest changes: the revaluation of technology and new approaches to R&D and product development. The most remarkable similarity: both at the beginning and end of IN VIVO's first decade, suppliers wanted to get into the service business.
You may also be interested in...
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 4)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this fourth installment of a 10-part series, the experts address so-called back rooms used by manufacturers during an inspection.
Recruiting generics firms to the AMR Industry Alliance is a key area of focus for the group as part of its efforts to cover a greater proportion of the global supply of antimicrobials, according to the Alliance’s latest report.
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.